linjc16/ctgov huggingface dataset:
An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to examine the transfusion rate and appropriateness in patients undergoing elective knee and hip replacement surgery at Siriraj Hospital

Detailed Description
-----------------
The main objective of this study is to examine the transfusion rate and appropriateness in patients undergoing elective knee and hip replacement surgery at Siriraj Hospita by reviewing data from previous medical records (retrospective chart review).

Official Title
-----------------
An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty in Siriraj Hospital: a Retrospective Study

Conditions
-----------------
Transfusion-dependent Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients Having elective Hip or Knee Arthroplasty in Siriraj Hospital Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative transfusion rate | Transfusion rate in Patients Having Hip or Knee Arthroplasty in Siriraj Hospital | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inappropriate transfusion rate | Perioperative inappropriate transfusion rate in Patients Having Hip or Knee Arthroplasty in Siriraj hospital | 1 week |
Mixed Reality Gaming for Chronic Low Back Pain

Study Overview
=================
Brief Summary
-----------------
Mixed Reality Gaming for Chronic Low Back Pain

Detailed Description
-----------------
The company, From the Future and University of Alabama at Birmingham (UAB) team aimed to develop a virtual reality (VR) game that integrated with the features of a specialized self-driven treadmill to provide accessible and progressive walking challenges for individuals with chronic low back pain (LBP). The game was designed to go beyond typical VR research efforts and provide a truly immersive and engaging experience that would motivate individuals with high pain-related fear to keep moving.

Official Title
-----------------
Mixed Reality Gaming for Chronic Low Back Pain

Conditions
-----------------
Recurrent Low Back Pain

Intervention / Treatment
-----------------
* Device: Exergaming


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of chronic low back pain Exclusion Criteria: No major neurological, cardiac, pulmonary, or other orthopedic injuries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exergaming<br> | Device: Exergaming<br>* Mixed Reality Gaming for Chronic Low Back Pain<br>* Other names: Mixed Reality;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Walking Distance | How far participants walk while playing the game as measured by a meter on the instrumented treadmill. | Day 1 through Day 3 of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Walking Speed | How fast participants walk while playing the game by dividing the distance people walked by the amount of time that they walked | Day 1 - Day 3 of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Walking, Exercise, Exergaming
Safety and Efficacy of DUO Extended Set: Combined Glucose Sensor and Infusion Set.

Study Overview
=================
Brief Summary
-----------------
The study will follow subjects for 28 days while using an DUO extended infusion set combined with glucose sensor. the objective is to evaluate saftey and efficacy of the set in adult patient with type 1 diabetes.

Official Title
-----------------
Safety and Efficacy of DUO Extended Set: Combined Glucose Sensor and Infusion Set.

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Device: DUO Extended Set


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of type 1 diabetes for at least one year Using a MiniMed™ 670G or 640G Insulin pump with Guardian sensor Age 18 to 80 years Hemoglobin A1c level less than or equal to 10% Not currently known to be pregnant, nor planning pregnancy during the study. Willingness to follow the protocol and sign the informed consent Exclusion Criteria: A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. Pregnant or lactating females Subject has Glycosylated hemoglobin (HbA1c) > 10 % at time of screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1st arm<br>Wearing the Duo infusion set for up to 1 month or up to 4 infusion set failures. | Device: DUO Extended Set<br>* to evaluate saftey and efficacy of DUO extended set combined with glucose sensor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primery Effectivness Endpoint | Precent of catheters reaching 7- day without set failure. | 28 days |
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Study Overview
=================
Brief Summary
-----------------
This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.

Official Title
-----------------
A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury

Conditions
-----------------
Acquired Bleeding Disorder, Trauma

Intervention / Treatment
-----------------
* Drug: activated recombinant human factor VII


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages Eligible for Study: 18 Years - 85 Years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Factor VII<br> | Drug: activated recombinant human factor VII<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
BK Treatment Study

Study Overview
=================
Brief Summary
-----------------
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or eliminating BK virus in the blood.

Official Title
-----------------
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study

Conditions
-----------------
BK Viremia

Intervention / Treatment
-----------------
* Drug: levofloxacin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living and cadaveric kidney transplant recipients over the age of 18 years with BK viremia Exclusion Criteria: Female patients of childbearing age who are pregnant or in whom adequate contraception cannot be maintained. Patients with active infections, history of malignancy/Posttransplant Lymphoproliferative Disease (PTLD) serologic positivity to HIV. Patients with evidence of urinary tract obstruction causing allograft dysfunction, unless corrected by time of enrollment. Patients with clinical or morphological evidence of recurrence of primary disease. Patients with a history of allergic reaction to quinolone antibiotics. Patients with history of prolong QT interval Patients with recurrent hypoglycemic episodes Patients with history of myasthenia gravis Patients taking Thioridazine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Levofloxacin<br>Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days | Drug: levofloxacin<br>* 500 mg tablet, daily, 30 days<br>* Other names: Levaquin;|
| Placebo Comparator: placebo<br>placebo identical to levofloxacin drug daily for 30 days | Drug: placebo<br>* no dose, tablet, daily, 30 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline in BK Virus Copies at 3 Months | Percent change in BK virus copies/mL from Baseline to 3 months | Baseline and 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With >50% Reduction in BK Virus Copies | Number of patients with >50% reduction in BK viral load at 6 months | Baseline and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BK viremia, kidney transplantation, BK viremia in kidney transplant recipients
Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.

Study Overview
=================
Brief Summary
-----------------
This is a prospective, observational study, aimed to establish the relationship between an inefficient endogenous pain modulation before surgery (total knee arthroplasty; TKA) and the probability to develop chronic pain after surgery (persistent post surgical pain). Endogenous analgesia efficiency will be measured during the month previous to surgery using quantitative sensory testing (QST). Persistent post surgical pain will be defined as presence of pain in movement greater than 3 points in a 0-10 numerical scale in the operated knee, 6 months after surgery.

Official Title
-----------------
Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Behavioral: Quantitative sensory testing (QST)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 18 patients Scheduled for primary total knee arthroplasty Disposition to visits and scheduled tests Exclusion Criteria: Previous surgery on knee to be operated Documented peripheral neuropathy Severe disease or condition that could potentially interfere with interpretation of tests.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with knee osteoarthritis<br> | Behavioral: Quantitative sensory testing (QST)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of pain in the operated knee, 6 months after surgery. |  | Presence of pain greater than 3 points in a 0-10 numerical scale in the operated knee, 6 months after surgery. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endogenous Analgesia efficiency measured with QST (Quantitative sensory testing) techniques. |  | From start of recruitment untill day 180. |
Pilot Study to Determine the Effectiveness of Antimicrobial Healthcare Worker's (HCW) Hands and Clothing

Study Overview
=================
Brief Summary
-----------------
This is a pilot study to determine the effectiveness of antimicrobial scrubs on bacterial burden of HCW's hands and clothing in a clinical setting.

Detailed Description
-----------------
Goals of the pilot study: Compare CFU counts on antimicrobial vs standard scrubs in a clinical setting Assess CFU counts on the hands of HCWs wearing antimicrobial vs non-antimicrobial scrubs Assess HCW hand hygiene compliance during the study protocol Correlate device associated infection rates during protocol to historical controls Assess feasibility of applying protocol to a longer,12-24 month, prospective crossover-trial to definitively study and assess the impact of antimicrobial scrubs on HCW apparel and hand colonization, control of multi-drug resistance organisms, hand hygiene compliance, and device associated hospital acquired infection rates. II. Design Cross-over trial in an ICU or Hospital Ward III. Outcome Measures CFU count on participants Hands Scrubs Antimicrobial scrubs vs standard scrubs Hand Hygiene Compliance Device associated nosocomial infections rates

Official Title
-----------------
Pilot Study to Determine the Effectiveness of Antimicrobial Scrubs on Bacterial Burden of HCW's Hands and Clothing in a Clinical Setting

Conditions
-----------------
Effectiveness of Antimicrobial Impregnated Scrubs in a Healthcare Setting

Intervention / Treatment
-----------------
* Other: Vestagen scrubs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HCWs in the MRICU Exclusion Criteria: Under the age of 18 who is not a healthcare worker in the MRICU

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exp Scrubs<br>antimicrobial impregnated scrubs | Other: Vestagen scrubs<br>* antimicrobial impregnated textile<br>* Other names: Nanosphere;|
| No Intervention: Non-antimicrobial scrubs<br>Non-antimicrobial scrubs | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness of Antimicrobial impregnated scrubs |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HCW hand and scrub average bacterial counts |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CFU, antimicrobial, epidemiology, bacteriology
Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren

Study Overview
=================
Brief Summary
-----------------
A large study in Mallorca, Spain showed that nonspecific low back pain is quite prevalent in adolescents 13-15 years of age (Kovacs, 2003). Since below the age of seven years hardly any child has suffered low back pain, the purpose of this study is to determine the prevalence of low back pain in children 10-12 years of age, and to investigate the risk factors associated with its occurrence.

Official Title
-----------------
Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Other: Measurement, weight, and muscle strength test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schoolchildren born in the years 1993, 1994 or 1995 Attending schools (public, concerted or private) in Mallorca Can read and write Spanish Exclusion Criteria: Nor attending class on the days when the study is being done

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nonspecific low back pain, schoolchildren, prevalence
Real-life Cohort of Patients With Chronic Hepatitis B Virus Infection

Study Overview
=================
Brief Summary
-----------------
It is estimated that 350-400 million people worldwide are chronically infected with hepatitis B virus (HBV). Cirrhosis and hepatocellular carcinoma are major complications of chronic HBV infection and are responsible of about 500,000 deaths each year. Although some predictive factors of the outcome of chronic HBV infection were reported, it remains needed to more precisely determine the factors which are associated with the outcome in non-selected patients. Indeed, these factors should help to identify patients who are likely to have a better or worse evolution of their chronic HBV infection over time and thus, to adapt their clinical management and monitoring.Therefore, our purpose is to constitute a real-life cohort of non-selected patients to create a database of epidemiological, clinical, biological, virological and therapeutic parameters, in order to determine factors associated with the outcome of chronic HBV infection.

Official Title
-----------------
Hepatitis B Cohort: Predictive Factors of the Outcome of Chronic Hepatitis B Virus Infection

Conditions
-----------------
Hepatitis B

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic HBV infection (defined as HBsAg positive for at least 6 months) Exclusion Criteria: Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and/or hepatitis D virus (HDV) Decompensated cirrhosis History of liver transplantation History of hepatocellular carcinoma (HCC)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with chronic hepatitis B virus infection<br>Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine factors associated with the outcome of chronic HBV infection |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis B
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography

Study Overview
=================
Brief Summary
-----------------
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg regions) for visualization of arteries, evaluating 179 not assessable: caused by contrast media in the evaluation of structural abnormalities. Magnevist (SH L 451 A) was administered intravenously in a crossover design in patients with arterial disease in the abdominal to leg regions. The safety of the 0.2 mmol/kg dose was also assessed.

Official Title
-----------------
Evaluation of a Single Intravenous Injection of Magnevist (SH L 451 A) at 0.1 mmol/kg and 0.2 mmol/kg in Contrast-enhanced 3D-Magnetic Resonance Angiography in Patients With Arterial Disease in the Abdominal to Leg Regions in the Ability of Detecting of Vessel Abnormalities

Conditions
-----------------
Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases

Intervention / Treatment
-----------------
* Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
* Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are scheduled to undergo contrast-enhanced 3D-Magnetic Resonance Angiography Exclusion Criteria: Patients with an ankle brachial pressure index (ABPI) of 0.3 or less Patients with allergy to contrast media Patients with serious hepatic impairment Patients with serious renal impairment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Arm 1<br> | Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)<br>* Magnevist at a dose of 0.1 mmol/kg<br>|
| Experimental: Arm 2<br> | Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)<br>* Magnevist at a dose of 0.2 mmol/kg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic ability |  | MRI image in blinded read | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visibility |  | MRI image in blinded read | 
| Diagnostic confidence |  | MRI image in blinded read | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnevist, Magnetic Resonance Angiography, Meglumine gadopentetate, Determination of effective dose in MRA